Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 05, 2019 01:00 ET | Source: ObsEva SA

ObsEva Reports Fourth Quarter and Full Year 2018 Financial Results, Provides Business Update

Major 2018 Accomplishments Driven by Positive Clinical Trial Results -Significant increase in rates of pregnancy and live birth (up to 35% increase in Day 5 ET) in Phase 3...
February 27, 2019 01:00 ET | Source: ObsEva SA

ObsEva SA to Hold Fourth Quarter and Full Year 2018 Financial Results and Business Update Call on March 5, 2019

Geneva, Switzerland and Boston, MA –February 27, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of...
February 22, 2019 01:00 ET | Source: ObsEva SA

ObsEva SA to Participate in Upcoming Investor Conferences

Geneva, Switzerland and Boston, MA – February 22, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
January 23, 2019 03:28 ET | Source: ObsEva SA

Update: ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women with Preterm Labour and Announces Start of Part B of the PROLONG Trial

Geneva, Switzerland and Boston, MA – January 23, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
January 23, 2019 01:00 ET | Source: ObsEva SA

ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women with Preterm Labour and Announces Start of Part B of the PROLONG Trial

Geneva, Switzerland and Boston, MA – January 23, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
January 02, 2019 01:00 ET | Source: ObsEva SA

ObsEva SA to Participate in JP Morgan Healthcare Conference January 7-10, 2019

Geneva, Switzerland and Boston – January 2, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
December 21, 2018 01:00 ET | Source: ObsEva SA

ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 2 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids

Geneva, Switzerland and Boston, MA – December 21, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical- stage biopharmaceutical company focused on the development and commercialization of novel therapeutics...
December 07, 2018 12:12 ET | Source: ObsEva SA

ObsEva R&D Day Showcases Multiple Women’s Health Programs and Outlines Plans for Transition to Commercial Operations

Clinical Trial Data and Regulatory Progress on Lead Programs Targeting IVF, Endometriosis, and Uterine Fibroids to Transform Company in 2019 GENEVA, Switzerland and BOSTON, Mass. (December...
December 06, 2018 01:00 ET | Source: ObsEva SA

ObsEva SA to Participate in BMO Healthcare Conference December 12, 2018

Geneva, Switzerland and Boston, MA – December 6, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
November 29, 2018 01:30 ET | Source: ObsEva SA

ObsEva SA to Host R&D Investor Day December 7, 2018

Geneva, Switzerland and Boston, MA – November 29, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics...